Vertex Pharmaceuticals Incorporated
Foreign stocks · NASDAQ · Healthcare · Pharmaceuticals
Develops and sells drugs mainly for cystic fibrosis (an inherited lung disease), and is expanding into pain treatments and gene therapy. Almost all revenue comes from prescription drug sales
For every 100 dollars of sales: cost of sales 14 · operating expenses 51 · other items 0 · tax and other items 2 · leaving 33 as net profit
Investors in Thailand can buy VRTX through 13 mutual funds open to retail investors. Most of them (13 funds) don't buy the stock themselves. Instead they invest in a master fund abroad, which in turn holds VRTX.
| Fund | VRTX weight | How it invests | 1-year return |
|---|---|---|---|
 SCBIHEALT(SSFE)SCB Healthcare Innovation | 4.83% | Via BNP Paribas Funds Health Care Innovators | +15.53% |
 LHHEALTH-ALH HEALTH INNOVATION FUND | 3.66% | Via AB International Health Care Portfolio | +18.58% |
 DAOL-GIHEALTHDAOL GLOBAL INNOVATIVE HEALTHCARE FUND | 3.48% | Via Janus Henderson Horizon Biotechnology Fund | +2.88% |
 TGHDIGITISCO Global Digital Health Equity Fund | 2.69% | Via UBS (Lux) Digital Health Equity | +3.88% |
 UHCRMFUnited Global Healthcare RMF | 2.64% | Via United Global Healthcare Fund | +15.57% |
| UGHUnited Global Healthcare Fund | 2.61% | Via United Global Healthcare Fund | +15.64% |
| UOBSHCUOB Smart Global Healthcare Fund | 2.61% | Via United Global Healthcare Fund | +15.82% |
 ASP-IHEALTHAsset Plus Innovative Healthcare Fund | 2.35% | Via several master funds (JHHBIU2 LX, ARKG US) | +20.72% |
 BCARERMFBualuang Global Health Care RMF | 2.29% | Via Wellington Global Health Care Equity Fund | +22.64% |
| BCAREBualuang Global Health Care Fund | 2.28% | Via Wellington Global Health Care Equity Fund | +23.02% |
Yearly average over the last 4 years · Latest annual sales 12.0B USD
For every 100 dollars of sales, about 33 dollars is left as net profit
Per year, relative to the share price · Tech stocks tend to pay little because they reinvest their profits
Now 1.8% below its 1-year high
| Item (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenue | 7.6B USD | 8.9B USD | 9.9B USD | 11.0B USD | 12.0B USD |
| Gross profit | 6.7B USD | 7.9B USD | 8.6B USD | 9.5B USD | 10.4B USD |
| Operating profit | 2.8B USD | 4.3B USD | 3.8B USD | −233.0M USD | 4.2B USD |
| Net profit | 2.3B USD | 3.3B USD | 3.6B USD | −536.0M USD | 4.0B USD |
| EPS (diluted) | 9.01 | 12.82 | 13.89 | −2.08 | 15.32 |
| Gross margin | 88.1% | 87.9% | 87.2% | 86.1% | 86.2% |
| Operating margin | 36.7% | 48.2% | 38.8% | −2.1% | 34.8% |
| Net margin | 30.9% | 37.2% | 36.7% | −4.9% | 32.9% |
| Operating cash flow | 2.6B USD | 4.1B USD | 3.5B USD | −493.0M USD | 3.6B USD |
| Free cash flow | 2.4B USD | 3.9B USD | 3.3B USD | −790.0M USD | 3.2B USD |
| Total assets | 13.4B USD | 18.2B USD | 22.7B USD | 22.5B USD | 25.6B USD |
| Total liabilities | 3.3B USD | 4.2B USD | 5.2B USD | 6.1B USD | 7.0B USD |
| Shareholders' equity | 10.1B USD | 13.9B USD | 17.6B USD | 16.4B USD | 18.7B USD |
| Period | SMA | EMA | Price vs line |
|---|---|---|---|
| 10 days | 535.91 | 536.11 | Above |
| 20 days | 520.64 | 527.90 | Above |
| 50 days | 522.90 | 519.42 | Above |
| 100 days | 508.99 | 506.67 | Above |
| 200 days | 480.77 | 487.91 | Above |
| Indicator | Value | Signal |
|---|---|---|
| RSI(14) | 59.33 | Up |
| MACD(12,26) | 8.42 | Up |
| ADX(14) | 23.98 | Neutral |
| ATR(14) % of price | 1.80 | Neutral |
The many funds holding less than 3% are usually index funds holding at market weight · Funds holding more than 8% have deliberately chosen a large position
UOBAM3BBLAM3
KASSET2SCBAM1LHFUND1DAOLINV1TISCOASSET1ASSETFUND1| Fund | VRTX weight | Master fund | 1-year return | TER |
|---|---|---|---|---|
| SCBIHEALT(SSFE) | 4.83% | BNP Paribas Funds Health Care Innovators | +15.53% | 0.11% |
| LHHEALTH-A | 3.66% | AB International Health Care Portfolio | +18.58% | 2.16% |
| DAOL-GIHEALTH | 3.48% | Janus Henderson Horizon Biotechnology Fund | +2.88% | 2.32% |
| TGHDIGI | 2.69% | UBS (Lux) Digital Health Equity | +3.88% | 1.29% |
| UHCRMF | 2.64% | United Global Healthcare Fund | +15.57% | 1.86% |
| UGH | 2.61% | United Global Healthcare Fund | +15.64% | 1.88% |
| UOBSHC | 2.61% | United Global Healthcare Fund | +15.82% | 1.86% |
| ASP-IHEALTH | 2.35% | several master funds (JHHBIU2 LX, ARKG US) | +20.72% | 2.83% |
| BCARERMF | 2.29% | Wellington Global Health Care Equity Fund | +22.64% | 1.48% |
| BCARE | 2.28% | Wellington Global Health Care Equity Fund | +23.02% | 1.24% |
| BCARESSF | 2.27% | Wellington Global Health Care Equity Fund | +22.81% | 1.23% |
| K-GNEXT-A(A) | 1.79% | Capital Group New Economy Fund (LUX) – Class Z (USD) | +4.65% | 1.70% |
| K-GNEXTRMF | 1.76% | Capital Group New Economy Fund (LUX) – Class Z (USD) | N/A | 1.66% |
| Master fund | Thai funds using this route | Master fund's VRTX weight |
|---|---|---|
| United Global Healthcare Fund | 3 | 2.64% |
| Wellington Global Health Care Equity Fund | 3 | 2.29% |
| Capital Group New Economy Fund (LUX) – Class Z (USD) | 2 | 1.79% |
| BNP Paribas Funds Health Care Innovators | 1 | 4.83% |
| AB International Health Care Portfolio | 1 | 3.66% |
| Janus Henderson Horizon Biotechnology Fund | 1 | 3.48% |
| UBS (Lux) Digital Health Equity | 1 | 2.69% |
| several master funds (JHHBIU2 LX, ARKG US) | 1 | 2.35% |
